|
Blumenstein et al. 201555
|
SAPIEN XT (n=19),
CoreValve (n=10),
ACURATE (n=4),
Other (n=2)
|
13.3%
|
94.3%
|
77.1%
|
97.1%
|
79.4%
|
n=8; 100%
|
|
Boukantar et al. 201766
|
CoreValve (n=16)
|
43.8%
|
58%
|
16%
|
75%
|
44%
|
n=7; 85.7%
|
|
Htun et al. 201767
|
CoreValve (n=28)
|
90.0%
|
100%
|
90%
|
100%
|
97%
|
n=29; 100%
|
|
Zivelonghi et al. 201754
|
Evolut R (n=25),
SAPIEN 3 (n=41)
|
0%
|
100%
|
94%
|
98%
|
97%
|
n=17; 100%
|
|
Tanaka et al. 201961
|
CoreValve/Evolut (n=41)
|
56.5%
|
50%
|
31.3%
|
87.5%
|
57.1%
|
n=30; 93.3%
|
|
Ferreira-Neto et al. 201953
|
SAPIEN XT (n=28)
|
64.3%
|
100%
|
81.5%
|
100%
|
82.6%
|
n=13; 100%
|
|
Couture et al. 202097
|
Evolut R/PRO (n=10)
|
10.0%
|
NA
|
60%
|
NA
|
40%
|
n=2; 50%
|
|
Nai Fovino et al. 202052
|
SAPIEN XT/3 (n=36),
CoreValve/Evolut R/Pro (n=8),
Jena (n=2),
Lotus (n=2)
|
35.0%
|
100% IA vs 75% SA
|
94% IA,
vs 25% SA
|
100% IA,
vs 100% SA
|
97% IA,
vs 50% SA
|
n=26; 96.2%
|
|
Barbanti et al. 202051
|
SAPIEN (n=96),
Evolut (n=123),
ACURATE (n=72),
Portico (n=9)
|
0%
|
96.0%
|
88.0%
|
95.3%
|
68.3%
|
n=0; 0%
|
|
Kim et al. 202198
|
SAPIEN (n=201),
ACURATE (n=62),
CoreValve/Evolut (n=140),
Portico (n=16),
Other (n=30)
|
100%
|
98.3%
|
71.6%
|
99.3%
|
79.3%
|
n=243; 91.4%
|
|
ACS: acute coronary syndrome; IA: intra-annular; CA: coronary access; LCA: left coronary artery; PCI: percutaneous coronary intervention; RCA: right coronary artery; SA: supra-annular; TAVI: transcatheter aortic valve implantation; THV: transcatheter heart valve
|
